Based on calculation of the ratio of CD8+ T cells within the tumor mass and neutrophils in the stroma, the authors were able to calculate a CD8+ cell/neutrophil (CD66 b+) ratio, with lower ratios being predictive of poor responsiveness to immunotherapy (Kargl et al., 2019). The gene discussed is CD8A; the disease is neoplasm.